Based on recent data, UroGen Pharma Ltd. (URGN) shows an Average True Range (ATR) of 1.36 and an Enterprise Value of 489.27M. Its average trading volume over the past 3 months is 807.59K, indicating liquidity. These fundamental metrics provide insight into URGN's underlying financial health and market activity.
| ATR | 1.36 |
| Enterprise Value | 489.27M |
| Avg Vol (3 Months) | 807.59K |
| Avg Vol (10 Days) | 774.33K |
UroGen Pharma Ltd. (URGN) technical indicators as of July 9, 2026: the SMA 20 is 1.62%, SMA 50 at -1.01%, and SMA 200 at 16.58%. The RSI 14 value is 51.02, suggesting its current momentum. These technical analysis signals help assess URGN's price trends and potential future movements.
| SMA 20 | 1.62% |
| SMA 50 | -1.01% |
| SMA 200 | 16.58% |
| RSI 14 | 51.02 |
UroGen Pharma Ltd. (URGN) stock performance overview as of July 9, 2026: The 52-week high is $40.34 (currently -29.4% below), and the 52-week low is $13.55 (currently 519.3% above). Over the past year, URGN's performance is 83.75%, compared to the S&P 500's 5.45% change.
| 52-Week High | 40.34 |
| 52-Week High Chg | -29.40% |
| 52-Week Low | 13.55 |
| 52-Week Low Chg | +519.30% |
| S&P 500 52-Week Chg | 5.45% |
According to market data, UroGen Pharma Ltd. (URGN) stock's recent performance metrics show that over the last month, URGN is -14.54%, with a Year-to-Date (YTD) performance of -17.46%. Over the past year, the stock has seen a 83.75% change. These figures summarize URGN's price movements across various periods, reflecting its historical returns.
| Period | 1 Week | 1 Month | Quarter | Half Year | 1 Year | YTD |
|---|---|---|---|---|---|---|
| High | 40.34 | 40.34 | 40.34 | 40.34 | 40.34 | 40.34 |
| Low | 36.55 | 26.6 | 17.75 | 16.5 | 13.55 | 16.5 |
| Performance | -9.88% | -14.54% | +14.04% | +25.03% | +83.75% | -17.46% |
According to current financial data, URGN stock's P/E (TTM) ratio is -14.51, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.22. Key valuation ratios for URGN, including P/S (13.84), P/B (-16.11), and P/FCF (-11.71), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.
| Valuation | URGN | Sector Median | Industry Avg | S&P 500 |
|---|---|---|---|---|
| P/E (TTM) | -14.51 | -1.22 | -194.02 | 32.59 |
| P/S (TTM) | 13.84 | 3.68 | 466.98 | 5.98 |
| P/B (TTM) | -16.11 | -0.57 | 11.22 | 5.25 |
| P/FCF (TTM) | -11.71 | 389.79 | -613.7 | 29.69 |
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep